Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on September 19, 2019. The company is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol "TROV".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.
Material Changes
The material event reported is the successful completion of the Phase 1b clinical trial of the company's drug candidate, onvansertib, in combination with standard-of-care chemotherapy for acute myeloid leukemia (AML). Consequently, the company has initiated patient enrollment in the Phase 2 trial.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the Phase 1b trial completion and the transition to Phase 2. The filing does not contain specific financial guidance, updated risk factors, or details on contingencies beyond the clinical trial progress. The press release detailing the event is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the clinical data and safety profile of onvansertib from the attached press release (Exhibit 99.1).
- Confirm the timeline and design of the newly initiated Phase 2 trial.
- Review the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor future filings for updates on Phase 2 enrollment rates and interim data readouts.